Search

Displaying results 7401 - 7410 of 7655 in total
  1. Drug

    E5531

    go.drugbank.com/drugs/DB06447
    Experimental

    E5531 is an endotoxin antagonist.

  2. Drug

    Levovirin

    go.drugbank.com/drugs/DB06523
    Experimental

  3. Drug

    N-chlorotaurine

    go.drugbank.com/drugs/DB06633
    Experimental

    N-chlorotaurine is an inhibitor of inducible nitric oxide synthase and IkappaB kinase.

  4. Drug

    Ranpirnase

    go.drugbank.com/drugs/DB04950
    Investigational

    Ranpirnase is a ribonuclease enzyme found in Rana pipiens oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.

  5. Drug

    Bectumomab

    go.drugbank.com/drugs/DB04962
    Experimental

    Bectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.

  6. Drug

    Besifovir dipivoxil

    go.drugbank.com/drugs/DB05020
    Investigational

    Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhib...

  7. Drug

    R1626

    go.drugbank.com/drugs/DB05060
    Experimental

    R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors. It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effe...

  8. Drug

    Elsamitrucin

    go.drugbank.com/drugs/DB05129
    Investigational

    The cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)

  9. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion by H. pylori.

  10. Drug

    BTA9881

    go.drugbank.com/drugs/DB05226
    Investigational

    BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.